Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 120


Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-Based Tuberculosis Clinic.

Gaensbauer J, Aiona K, Haas M, Reves R, Young J, Belknap R.

Pediatr Infect Dis J. 2017 Aug 1. doi: 10.1097/INF.0000000000001721. [Epub ahead of print]


Is it time to rethink the role of AFB smears?

Belknap R, Reves R.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):720. doi: 10.5588/ijtld.17.0323. No abstract available.


Correction for De Groote et al., "Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection".

De Groote MA, Higgins M, Hraha T, Wall K, Wilson ML, Sterling DG, Janjic N, Reves R, Ochsner UA, Belknap R.

J Clin Microbiol. 2017 May;55(5):1598. doi: 10.1128/JCM.00333-17. No abstract available.


The cost of the failure to eliminate tuberculosis in the United States.

Reves R, Benjamin R.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):120. doi: 10.5588/ijtld.16.0708. No abstract available.


Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection.

De Groote MA, Higgins M, Hraha T, Wall K, Wilson ML, Sterling DG, Janjic N, Reves R, Ochsner UA, Belknap R.

J Clin Microbiol. 2017 Feb;55(2):391-402. doi: 10.1128/JCM.01646-16. Epub 2016 Nov 16. Erratum in: J Clin Microbiol. 2017 May;55(5):1598.


Screening for Latent Tuberculosis Infection: A Key Step Toward Achieving Tuberculosis Elimination in the United States.

Reves R, Daley CL.

JAMA Intern Med. 2016 Oct 1;176(10):1439-1440. doi: 10.1001/jamainternmed.2016.5464. No abstract available.


Blood transcriptional signatures for tuberculosis diagnosis: a glass half-empty perspective.

Walter ND, Reves R, Davis JL.

Lancet Respir Med. 2016 Jun;4(6):e28. doi: 10.1016/S2213-2600(16)30038-8. No abstract available.


High Rates of Tuberculosis and Opportunities for Prevention among International Students in the United States.

Collins JM, Reves RR, Belknap RW.

Ann Am Thorac Soc. 2016 Apr;13(4):522-8. doi: 10.1513/AnnalsATS.201508-547OC.


Tuberculosis Contact Investigations--United States, 2003-2012.

Young KH, Ehman M, Reves R, Peterson Maddox BL, Khan A, Chorba TL, Jereb J.

MMWR Morb Mortal Wkly Rep. 2016 Jan 1;64(50-51):1369-74. doi: 10.15585/mmwr.mm6450a1.


Blood Transcriptional Biomarkers for Active Tuberculosis among Patients in the United States: a Case-Control Study with Systematic Cross-Classifier Evaluation.

Walter ND, Miller MA, Vasquez J, Weiner M, Chapman A, Engle M, Higgins M, Quinones AM, Rosselli V, Canono E, Yoon C, Cattamanchi A, Davis JL, Phang T, Stearman RS, Datta G, Garcia BJ, Daley CL, Strong M, Kechris K, Fingerlin TE, Reves R, Geraci MW.

J Clin Microbiol. 2016 Feb;54(2):274-82. doi: 10.1128/JCM.01990-15. Epub 2015 Nov 18.


Transnational Record Linkage for Tuberculosis Surveillance and Program Evaluation.

Aiona K, Lowenthal P, Painter JA, Reves R, Flood J, Parker M, Fu Y, Wall K, Walter ND.

Public Health Rep. 2015 Sep-Oct;130(5):475-84.


Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.

Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium.

Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v. doi: 10.5588/ijtld.14.0829.


Preventing Infectious Pulmonary Tuberculosis Among Foreign-Born Residents of the United States.

Davidow AL, Katz D, Ghosh S, Blumberg H, Tamhane A, Sevilla A, Reves R; Tuberculosis Epidemiologic Studies Consortium.

Am J Public Health. 2015 Sep;105(9):e81-8. doi: 10.2105/AJPH.2015.302662. Epub 2015 Jul 16.


In reply.

Reves RR.

Int J Tuberc Lung Dis. 2015 Apr;19(4):495. doi: 10.5588/ijtld.14.0861-2. No abstract available.


Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.

Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium.

JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. Erratum in: JAMA Pediatr. 2015 Sep;169(9):878.


Latent tuberculous infection in the United States and Canada: who completes treatment and why?

Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, Blumberg HM, Venkatappa TK, Horsburgh CR, Colson PW; Tuberculosis Epidemiologic Studies Consortium (TBESC).

Int J Tuberc Lung Dis. 2015 Jan;19(1):31-8. doi: 10.5588/ijtld.14.0373.


Evaluation of QuantiFERON-TB gold in-tube and tuberculin skin tests among immigrant children being screened for latent tuberculosis infection.

Howley MM, Painter JA, Katz DJ, Graviss EA, Reves R, Beavers SF, Garrett DO; Tuberculosis Epidemiologic Studies Consortium.

Pediatr Infect Dis J. 2015 Jan;34(1):35-9. doi: 10.1097/INF.0000000000000494.


Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.

Reves R, Heilig CM, Tapy JM, Bozeman L, Kyle RP, Hamilton CD, Bock N, Narita M, Wing D, Hershfield E, Goldberg SV; Tuberculosis Trials Consortium.

Int J Tuberc Lung Dis. 2014 May;18(5):571-80. doi: 10.5588/ijtld.13.0304.


Update in tuberculosis and nontuberculous mycobacterial infections 2013.

Reves R, Schluger NW.

Am J Respir Crit Care Med. 2014 Apr 15;189(8):894-8. doi: 10.1164/rccm.201402-0210UP. Review. No abstract available.


Acceptability of interferon-gamma release assays among healthcare workers who receive routine employee tuberculosis testing.

Hirsch-Moverman Y, Wall K, Weinfurter P, Munk E, Moran JA, Maiuris A, Khan A, DeLuca N; TB Epidemiologic Studies Consortium.

Int J Occup Environ Health. 2013 Oct-Dec;19(4):319-24.


Supplemental Content

Loading ...
Support Center